Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) SVP John D. Quisel sold 13,000 shares of the stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $29.98, for a total transaction of $389,740.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $51.00.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% during mid-day trading on Friday, hitting $29.81. The stock had a trading volume of 140,234 shares. Acceleron Pharma has a one year low of $16.78 and a one year high of $57.89. The stock has a 50-day moving average of $29.63 and a 200-day moving average of $35.97. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings data on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.01. Analysts expect that Acceleron Pharma will post $-1.44 EPS for the current fiscal year.

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.